Home » Zykadia Wins FDA Priority Review in First-Line Metastatic NSCLC
Zykadia Wins FDA Priority Review in First-Line Metastatic NSCLC
Novartis has gained FDA Priority Review for the expanded use of Zykadia as a first-line treatment for patients with metastatic non-small cell lung cancer whose tumors are anaplastic lymphoma kinase-positive as detected by an FDA-approved test.
The FDA also granted a Breakthrough Therapy designation to Zykadia for the first-line treatment of patients with ALK+ metastatic NSCLC with brain metastases.
Upcoming Events
-
21Oct